Adiponectin level and severity of liver fibrosis in patients chronic hepatitis C with metabolic syndrome

• Published in: Zhurnal infektologii Vol. 10; no. 2; pp. 98 - 102
• Main Authors: Novikova, A. F., Konstantinov, D. Yu, Suzdaltsev, A. A., Verbovoj, A. F., Kosareva, O. V.
• Format: Journal Article
• Language: English; Russian
• Published: Journal Infectology 02.07.2018
• Subjects: adiponectin; chronic hepatitis c; degree of histological activity liver; liver fibrosis; metabolic syndrome
• ISSN: 2072-6732; 2499-9865
• DOI: 10.22625/2072-6732-2018-10-2-98-102

The purpose of the research is to determine the value of adiponectin levels in patients chronic hepatitis C with metabolic syndrome depending on the severity of fibrosis and  histological activity in the liver.Materials and methods. The research included 72 patients chronic  hepatitis C with metabolic syndrome. All patients underwent  calculation of body mass index, determination of adiponectin level in  serum. The stage of liver fibrosis and degree of histological activity  was determined according to METAVIR scale based on histological  research of biopsy specimens obtained at liver biopsy. The average  age in the research group amounted to 40,73±6,3 years. Prevailed patients with a body mass index of 26–30 kg/m² – 61,1%. All  patients had abdominal obesity, the gender differences in the  prevalence of abdominal obesity was not found. In 73.6% of cases, it  was patients with moderate or severe liver fibrosis; 44,4% –  moderate-severe and severe degree of histological activity. The  mean value of adiponectin is made up 9,36±3,28 microgram /ml.  Was an inverse relationship between body weight and adiponectin  level. The patients chronic hepatitis C with metabolic syndrome  found a significant reduction in levels of adiponectin, compared with healthy people. In women were observed significantly lower adiponectin levels compared to men (p<0,05). Feedback was installed between the body weight and level of adiponectin. Level of serum adiponectin in patients with chronic  hepatitis c with metabolic syndrome decreased with the progression of fibrosis and severity of pathological process activity in the liver.